Introduction
The pathogenesis of microvascular complications (neuropathy, retinopathy, and renal disease) in type 1 diabetes mellitus (T1DM) seems to be multifactorial. Genetic and environment factors contribute to their development and progression. It was suggested that certain groups of patients are prone to develop one or more of these microvascular disorders while others are genetically resistant. Recent reports have shown increased risk for polyneuropathy in GG homozygotes of endothelial nitric oxide synthase (eNOS) gene (the 894G>T polymorphism) [1] . Other groups have shown that eNOS 4ab [2] , -786T>C and -774C>T [3] polymorphisms affect the onset pattern of severe retinopathy, while eNOS -786T>C and 4ab [4] influence the risk of advanced diabetic renal disease. These findings provide further support for a genetic predisposition to diabetes-related to microvascular complications. Preservation of normal endothelial function depends on the bioavailability of nitric oxide (NO). In type 1 diabetic subjects prone to vascular complications high concentrations of serum NO metabolites (the stable end-product nitrite/nitrate, NOx) are frequently evident. It was reported that in early stages of diabetes pathological vasodilatation and reduced peripheral resistance occur. These vascular dysfunctions are associated with increased NO generation and activity [5] . On the other hand, hyperglycemia leads to an increased production of advanced glycation end products (AGEs) and low molecular weight-AGE species (LMW-AGEs), considered the "second generation" of AGEs, and both AGEs and LMW-AGEs contribute to the development of chronic microvascular complications in T1DM [6] .
Diabetic neuropathy, commonly manifested as distal symmetrical polyneuropathy is one of the most frequent chronic microvascular complications. In the peripheral nerve, persistent hyperglycemia leads to metabolic and vascular disorders responsible for nerve fiber abnormalities. It is evident that NO plays a regulatory role in the peripheral nervous system [7] , and recent reports have indicated that excessive local NO levels are present at sites of diabetic neuropathy [8] . Recently we showed a significant correlation between NO metabolites and LMW-AGEs and diabetic neuropathy in T1DM [9] .
Our study aimed to investigate the relationships between neuropathy in T1DM and polymorphisms of eNOS gene and, secondly, to determine the roles of NO metabolites and LMW-AGEs in this relationship. We genotyped the 894G>T and 4ab of eNOS gene and correlated these genotypes with diabetes-related biochemical changes and microvascular complications.
Experimental Procedures

Study groups
Type 1 diabetic subjects (n=211) all Romanian Caucasians, aged ≥ 16 years, without being related, were investigated in the clinical departments of the Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. NC Paulescu" (Bucharest, Romania). The selection of diabetic probands was made according to the guidelines of EURODIAB ACE epidemiological study protocol [10] . According to these guidelines those cases that had an abrupt onset with diabetic ketoacidosis or required insulin treatment with the necessity to initiate insulin therapy within the first month from diagnosis and continuous use of insulin ever since without interruption for more than 12 months were diagnosed as T1DM cases.
The diagnosis of associated microvascular disorders were based on the presence of diagnostic criteria used in the EURODIAB study [11] . Diabetic renal disease was based on the assessment of the urinary albumin excretion rate (UAER) from a 24 h urine collection. Patients with persistent microalbuminuria (UAER between 30 and 300 mg/24 h; at least two positive samples from three assays determined during a 6 week interval) or overt proteinuria (UAER higher than 3 mg/ml were considered to have diabetic renal disease. The diagnosis of diabetic retinopathy was made by ophthalmological examination of the retina after pupil dilation. The diagnosis of diabetic neuropathy was based on the presence of two or more from the following four criteria: 1) suggestive symptoms of neuropathy; 2) absence of at least two out of the four skeletal reflexes of the ankle or knee tendons; 3) decreased thermal, pressional or vibratory perception thresholds and 4) abnormalities of autonomic cardiovascular reflexes including loss of heart rate variability and postural hypotension with a fall in systolic blood pressure of 20 mm Hg or more, or both.
We previously used this T1DM group to estimate the relationship between LMW-AGEs and diabetesassociated microvascular complications; this study reported details on body mass index, fasting blood glucose, total cholesterol, triglycerides, HbA1c, systolic and diastolic blood pressure, and serum creatinine clearance [9] .
The patients were separated into groups according to complication status. Group I were patients without microvascular disorders (n=35). Group II were patients with neuropathy and normal kidney function (n=69); in this group 55.07% of the patients also had diabetic retinopathy (n=38). Group III were patients with neuropathy and associated-nephropathy (n=105); of which 85.71% (n=90) had all three microvascular disorders.
Non-diabetic sex and age-matched subjects (n=117) were employed as the control group and these subjects had normal baseline characteristics. Informed consent was obtained from all subjects and the study complied with all relevant national guidelines and institutional policy.
DNA polymorphism analysis
Genomic purified DNA extracted from peripheral blood leukocytes was used. For the polymorphic eNOS gene located on chromosome 7q35 to 36, the missense 894G>T (Glu298Asp) variant in exon 7, and the 27 bp tandem-repeat in intron 4 (4ab) polymorphism were analyzed [12] . Genotypes were determined using PCR and PCR-RFLP in T1DM and control subjects.
Polymorphism in exon 7 of the endothelial nitric oxide synthase gene is associated with low incidence of microvascular damage in type 1 diabetic neuropathy
Measurement of serum NO metabolites and LMW-AGEs
The stable end-product nitrite/nitrate (NOx) as the expression of NO bioavailability was determined as a marker for endothelial function. Measurements of serum NOx were performed with Griess reagents after incubation with nitrate reductase for enzymatic conversion [13] . The fluorescence (excitation at 370 nm and emission at 440 nm) of LMW-AGEs in serum samples and standard (digested human albumin-AGEs) were determined and the relative fluorescence/mg peptide/ml (absolute fluorescence, AF) was calculated.
The data were reported as AF% of the LMW-AGEs standard (1 mg peptide/ml gave 187 AF) as previously described [6, 9] .
Statistical analysis
Baseline characteristics of diabetic patients were compared with control by one-way ANOVA test and the data expressed as mean ± SD. The statistical differences in genotype distribution and allele frequencies between patients and controls were assessed by the Chi-squared test. The Hardy-Weinberg equilibrium was analyzed using the DeFinetti program (http://ihg.gsf.de/cgi-bin/hw/ hwa1.pl). All parameters entered in the linear regression were log transformed (for a normal distribution according to Skewness and Kurtosis normality test); the age-and sex-adjusted model was used for analysis. Continuous numeric data were converted in categorized variables for logistic regression analysis, and age-and sexadjusted model was used. P value ≤ 0.05 was accepted for significance. All data were analyzed using SPSS 10.0 software.
Results
Clinical characteristics of subjects are summarized in Table 1 . Controls and T1DM patients were matched for age and sex. As expected, compared with controls, significant differences were found in T1DM for glucose, triglycerides, systolic BP, serum creatinine and creatinine clearance. NOx levels were significantly elevated in T1DM subjects (44.6±19.6 µmol/L) as compared with controls (18.8±10.2 µmol/L). Serum LMW-AGEs levels were also significantly higher in T1DM patients as compared with non-diabetic subjects. In the T1DM group the level of triglycerides (logged transformed) correlated with eNOS 894G>T (χ2=5.67; P=0.059) by Kruskal-Wallis test. There were no significant relationships between the eNOS 4ab polymorphism and any of tested biological parameters. The relationship between eNOS 894G>T with logged measurements of parameters in T1DM (in an ageand sex-adjusted linear regression model) showed a trend toward lower levels of triglycerides, NOx, and LMW-AGEs as well as low systolic blood pressure with increased number of 894T alleles; importantly the relationship was statistically significant for logged triglycerides in the 894GT group (P=0.006).
We next examined whether diabetic microvascular complications are associated with the eNOS 894G>T polymorphism (Table 2 ). In the whole group of T1DM patients, 167 subjects (79.1%) had neuropathy, 130 subjects (61.6%) had retinopathy and 126 subjects (59.7%) had nephropathy. The prevalence of neuropathy was 87.72% in the 894GG group with a trend to lower incidence in the heterozygote 894GT group (74.07%; P=0.043) and the 894TT group (65.79%; P=0.012). There were non-significant correlations between diabetic retinopathy and renal disease within the eNOS 894G>T genotypes. Similarly, the eNOS 4ab polymorphism was not correlated with microvascular complications.
To appropriately assess the association between the eNOS 894G>T polymorphism and diabetic neuropathy, diabetic subjects without any vascular complications (group I) were compared with patients with neuropathy and normal kidney function (group II). Of these group Table 2 . Prevalence of microvascular disorders in type 1 diabetic subjects by eNOS 894G>T genotypes.
GG, GT, and TT, genotypes of eNOS 894G>T polymorphism; %, percentages of 894GG and 894TT homozygous and 894GT heterozygous with the respective vascular complication were calculated for each genotype from the whole type 1 diabetic subjects; OR, odds ratio; 95% C.I., confidence interval; P, significance were calculated by logistic regression analysis.
II subjects approximately 55% also had diabetic retinopathy. The logistic regression analysis indicated a non-significant association between eNOS 894G>T variant and neuropathy (OR=0.59; 95% C.I.=0.31-1.12; P=0.11). The presence or absence of retinopathy in group II did not modify the significance of the relationship between the eNOS 894G>T polymorphism and neuropathy (data not shown). Further, group II was combined with group III (patients with neuropathy and associated-nephropathy) and compared with diabetic subjects without any vascular complications. The regression analysis showed a significant association between eNOS 894G>T variant and neuropathy (OR=0.55; 95% C.I.=0.32-0.92; P=0.024), but not with nephropathy (P=0.95) or retinopathy (P= 0.73). When gender, age and duration of diabetes (the latter two being categorized variables) were introduced into the equation, the most significant factor was age (OR=2.35; 95% C.I.=1.26-4.41; P=0.008), followed by duration of diabetes (OR=2.07; 95% C.I.=1.18-3.65; P=0.012). The association between eNOS 894G>T polymorphism and diabetic neuropathy remained at the limit of significance (OR=0.44; 95% C.I.=0.19-1.02; P=0.056).
We also found that the eNOS 894G>T polymorphism was in a significant relationship with diabetic neuropathy (OR=0.15; 95% C.I.=0.034-0.65; P=0.011) and nephropathy (OR=0.26; 95% C.I.=0.076-0.87; P=0.029) when selected patients with neuropathy and associated nephropathy (group III) were compared with those without any vascular complications (group I); the analysis was performed according to gender, age and duration of diabetes. When HbA1c (as index for the severity of microvascular disease) was introduced into the equation the relationship was not significant and remained at the border of significance in both cases (P=0.075 for neuropathy and P=0.06 for nephropathy).
With the knowledge that nitric oxide is a suitable biomarker for endothelial dysfunction, the measurement of serum NOx was performed as a surrogate indicator for NO. Here, we questioned whether increased NOx levels correlated with eNOS 894G>T polymorphism. There was a trend to lower NOx levels with increasing number of 894T alleles in T1DM (59.48±7.69 µmol/L for 894GG versus 42.2±5.64 µmol/L for 894TT) as well as in subgroups of patients with or without microvascular complications, as in the case of group III (58.38±14.62 µmol/L for 894GG versus 40.91±5.67 µmol/L for 894TT). This correlation reached significance (standardized coefficient beta= -0.647; P=0.029) in the group of patients without microvascular complications, where NOx levels were low in the 894TT homozygotes (19.41±2.87 µmol/L), being close to levels of non-diabetic subjects. The concentration of LMW-AGEs showed a similar trend to NOx; in the 894TT homozygotes with neuropathy and nephropathy (group III) the measurements were 30.35±10.09 AF% as compared to 47.54±18.4 AF% in 894GG group.
Multiple logistic regression analysis (an ageand sex-adjusted model) confirmed a significant association between eNOS 894G>T polymorphism and diabetic neuropathy ( Table 3) . The relationship remained significant (P=0.025) in the presence of total cholesterol, triglycerides, systolic blood pressure, duration of diabetes, NOx and LMW-AGEs. From all these parameters, the most significant association with diabetic neuropathy was, firstly, duration of diabetes (OR=2.57; 95% C.I.=1.45-4.55; P=0.001) and, secondly, LMW-AGEs (OR=3.1; 95% C.I.=1.35-7.13; P=0.008). 
Discussion
Among our findings, the first note was the significant overrepresentation of the rare-type TT genotype of eNOS 894G>T polymorphism in diabetic patients without any clinically manifested microangiopathies compared to controls. Although NOx levels were significantly higher in T1DM subjects than in control subjects, in the 894TT homozygotes there was a lower NOx level both in patients without any vascular disorders and in those with neuropathy and kidney disorders as compared with wild-type 894GG homozygotes. The diminution of NOx level in 894T allele carriers suggested an allele dosageeffect with the subsequent reduction in NO synthesis. This finding was consistent with other findings regarding the functional variants in the eNOS gene. It was reported that the 894T allele reduces the expression of eNOS enzyme when increased proteolysis occurs and may decrease NOx levels [14] . Previous reports [5, 9, 15] showed significantly increased circulating NOx in diabetic patients. This strengthens the hypothesis that the pathogenesis of early diabetic-associated vascular complications is associated with a generalized increased synthesis of NO throughout the body. This phenomena occur early in the natural course of diabetes and independently of the presence of microvascular complications [16] . We propose that the high NOx levels that were found in diabetic patients (including those without any clinically manifested microangiopaties) might represent an overproduction of NO that is associated with diffuse endothelial dysfunction.
Equally interesting is the relationship between eNOS 894G>T polymorphism and diabetic neuropathy. This chronic life-threatening complication is partially induced by the impairment of blood flow at the level of both peripheral and autonomic nerves. Patients with mild to severe neuropathy show graded structural changes in nerve microvasculature including endothelial cell hyperplasia [17] . Microvascular endothelium is particularly vulnerable to hyperglycaemia and dyslipidaemia, leading to endothelial dysfunction. Reduced nerve perfusion and function, endoneurial hypoxia and subsequent low oxygen tension increases endothelial cell capacity to produce NO [18] .
In agreement with a recent report [1] we found a prevalence of neuropathy among the 894GG as compared with 894TT homozygotes in diabetic patients with normal kidney function, suggesting that 894GG genotype might be a risk factor for T1DM-related microvascular disease. These patients had retinopathy (over 42%) as an additional vascular complication; they also had high systolic blood pressure and high levels of NOx and triglycerides signifying both an endothelial dysfunction and a higher risk lipid profile, respectively. Circulating LMW-AGEs were also high, strengthening our previous report on the synergistic action of NOx and LMW-AGEs in endothelial activation with a subsequent role in the development of diabetic neuropathy [9] .
In contrast, diabetic 894TT homozygotes with neuropathy (with or without nephropathy) had significantly lower circulating NOx. It is also important to note that in 894TT diabetic homozygotes without clinically manifested vascular disorders the NOx concentrations showed a tendency towards the levels found in non-diabetic subjects. Our presumption is that the rare-type 894T allele might have a protective role against the risk of developing diabetic neuropathy and a tendency to counterbalance increased NO production due to both chronic hyperglycemia and hypoxic effect at the microvascular level by, an as yet to be elucidated, compensatory-type mechanism.
The number of patients only with neuropathy and with neuropathy and nephropathy were quite small and did not allow us to determine whether associations between the eNOS 894G>T polymorphism and neuropathy account particularly for this disorder or was influenced by the presence of nephropathy. However, in the mixed group of patients complicated with one to three microvascular disorders the association remained significant with neuropathy; the influence of nephropathy can not be excluded.
In conclusion, the overrepresentation of rare-type 894TT genotype of eNOS gene in T1DM is associated with a lower risk for neuropathy. Decreased NOx and LMW-AGEs levels and lower lipid profile are the main features seen in 894T allele carriers. The protective role of 894TT genotype against microvascular disorders would have noticeable clinical implications. For instance, in T1DM subjects, the treatment of 894G allele carriers with hyperlipidemia, may need to be more aggressive than in the 894TT homozygote subjects.
